Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Macular Degeneration Nonexudative”

223 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 223 results

Testing effectiveness (Phase 2)WithdrawnNCT02122159
What this trial is testing

Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration

Who this might be right for
Myopic Macular Degeneration
University of California, Los Angeles
Testing effectiveness (Phase 2)WithdrawnNCT04358471
What this trial is testing

Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Who this might be right for
Dry Age-related Macular DegenerationGeographic AtrophyGene Therapy+1 more
Hemera Biosciences
Not applicableEnded earlyNCT03894020
What this trial is testing

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

Who this might be right for
Dry Age-related Macular DegenerationMacular DegenerationRetinal Disease+3 more
Gyroscope Therapeutics Limited 83
Not applicableStudy completedNCT05447650
What this trial is testing

Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

Who this might be right for
Age-Related Macular DegenerationDry Age-related Macular DegenerationNonexudative Age-related Macular Degeneration
i-Lumen Scientific, Inc. 95
Not applicableStudy completedNCT06860568
What this trial is testing

The GA in HSI Study

Who this might be right for
Geographic AtrophyHealthy
Optina Diagnostics Inc. 42
Large-scale testing (Phase 3)Study completedNCT07214740
What this trial is testing

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

Who this might be right for
Geographic Atrophy Secondary to Age-related Macular Degeneration
Apellis Pharmaceuticals, Inc. 44
Early research (Phase 1)Study completedNCT03295877
What this trial is testing

Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Geographic Atrophy
Genentech, Inc. 28
Testing effectiveness (Phase 2)Looking for participantsNCT06659549
What this trial is testing

Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Who this might be right for
Geographic Atrophy of the Macula
Galimedix Therapeutics Inc 110
Early research (Phase 1)Study completedNCT04635800
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

Who this might be right for
Macular EdemaDiabetic Macular EdemaNeovascular Age-related Macular Degeneration+1 more
Novartis Pharmaceuticals 21
Not applicableEnded earlyNCT05200624
What this trial is testing

Subthreshold Laser Treatment in Intermediate Age-related Macular Degeneration With Nascent Geographic Atrophy Study

Who this might be right for
Age-Related Macular Degeneration
Center for Eye Research Australia 15
Testing effectiveness (Phase 2)Looking for participantsNCT07160179
What this trial is testing

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Who this might be right for
Geographic AtrophyAge-Related Macular Degeneration
AbbVie 66
Not applicableNot Yet RecruitingNCT07433088
What this trial is testing

Validation of Virtual Reality Tests for the Assessment of Patients With Age-related Macular Degeneration as Clinical Endpoints

Who this might be right for
Dry AMDGeographic AtrophyHealhty
Streetlab 60
Not applicableStudy completedNCT04723160
What this trial is testing

Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph

Who this might be right for
Diabetic RetinopathyRetinal Vein OcclusionRetinal Artery Occlusion+10 more
Visionary Intelligence Ltd. 748
Post-approval studies (Phase 4)Study completedNCT04774926
What this trial is testing

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 122
Not applicableLooking for participantsNCT07144137
What this trial is testing

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Who this might be right for
Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics 75
Not applicableActive Not RecruitingNCT06161584
What this trial is testing

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Who this might be right for
Geographic Atrophy
Apellis Pharmaceuticals, Inc. 300
Testing effectiveness (Phase 2)Study completedNCT02684578
What this trial is testing

Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

Who this might be right for
Age-Related Macular DegenerationMacular Degeneration, Age-RelatedDry Macular Degeneration+1 more
University of California, San Francisco 66
Early research (Phase 1)Study completedNCT06006585
What this trial is testing

Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Who this might be right for
Geographic Atrophy
Boehringer Ingelheim 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT07520318
What this trial is testing

This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.

Who this might be right for
Adults With Neovascular Age-related Macular Degeneration
Shenzhen Oculgen Biomedical Technology Co., Ltd. 255
Not applicableLooking for participantsNCT07502664
What this trial is testing

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Who this might be right for
Retinitis PigmentosaStargardt Macular DystrophyStargardt Disease+3 more
Ray Therapeutics, Inc. 25
Next Page